Definitive Healthcare Corp. has 4 Schedule 13D or 13G filings on record since 2026-02-09. 3 holders' latest filing reports 5% or more of class a common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Advent International, L.P. | 58.54% | 62,493,676 | SCHEDULE 13D, 2026-09-02 | 2026-09-01 |
| Jason Ronald Krantz | 17.6% | 22,497,978 | SCHEDULE 13D, 2026-09-02 | 2026-09-01 |
| The Goldman Sachs Group, Inc. | 5.7% | 5,935,933 | SCHEDULE 13G/A, 2026-02-09 | 2025-12-31 |
Purpose of Transaction (Item 4)
Advent International, L.P.
Proposal On September 1, 2026, Advent LP, on behalf of the Advent GPE IX Funds (as defined herein) and the Advent Global Technology Funds (as defined herein) (collectively, the "Advent Funds") submitted a preliminary non-binding indication of interest ("Proposal") to the Special Committee (the "Special Committee") of the Board of Directors of the Issuer related to the proposed acquisition by the Advent Funds of all the outstanding shares of the Issuer's Common Stock and all of the outstanding limited liability company interests of AIDH TopCo, LLC (the "Definitive OpCo Units"), in each case, that are not already owned by the Advent Funds and Jason Krantz for an all-cash purchase price of $1.02 per share of Common Stock and an equivalent amount per Definitive OpCo Unit (the "Proposed Transaction"). The Proposal is premised on Mr. Krantz, Executive Chairman and founder of the Issuer, rolling over his Common Stock and Definitive OpCo Units into equity of the surviving company. Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee and approval by any applicable regulatory authorities. No assurance can be given that any definitive agreement will be entered into, that the Proposed Transaction will be consummated, or that the Proposed Transaction will be consummated on the terms set forth in the Proposal. Each of the Reporting Persons reserves the right to …The first part of Item 4 of the SCHEDULE 13D filed 2026-09-02; the filing has the rest
Jason Ronald Krantz
Since February of 2022, the Reporting Person has filed a Statement of Beneficial Ownership on Schedule 13G and amendments thereto with respect to his beneficial ownership in the Issuer. As a result of the Proposal by the Advent Funds described below, which is premised on the Reporting Person's participation through a roll over arrangement, the Reporting Person is now converting his beneficial ownership filing on Schedule 13G to a filing on this Schedule 13D. On September 1, 2026, Advent International, L.P., on behalf of certain of its managed funds (the "Advent Funds"), submitted a preliminary non-binding indication of interest ("Proposal") to the Special Committee (the "Special Committee") of the Board of Directors of the Issuer related to the proposed acquisition by the Advent Funds of all the outstanding shares of the Issuer's Class A Common Stock and all of the LLC Units, in each case, that are not already owned by the Advent Funds and the Reporting Person for an all-cash purchase price of $1.02 per share of Class A Common Stock and an equivalent amount per LLC Unit (the "Advent Proposed Transaction"). Based on the Schedule 13D filed by the Advent Funds on September 2, 2026 (the "Advent Schedule 13D"), the Advent Funds have beneficial ownership of approximately 58.54% of the Issuer. The Proposal states that it is premised on the Reporting Person rolling over all his Class A Common Stock and LLC Units into equity of the surviving company. The Proposal also states that …The first part of Item 4 of the SCHEDULE 13D filed 2026-09-02; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-09 | The Goldman Sachs Group, Inc. | 5.7% | SCHEDULE 13G/A |
| 2026-05-14 | Advent International, L.P. | 59.82% | SCHEDULE 13G/A |
| 2026-09-02 | Advent International, L.P. | 58.54% | SCHEDULE 13D |
| 2026-09-02 | Jason Ronald Krantz | 17.6% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Definitive Healthcare Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.